


PHT-7.3

Cat. No.:	HY-128590		
CAS No.:	1614225-93-2		
Molecular Formula:	C ₂₄ H ₂₃ N ₃ O ₃ S		
Molecular Weight:	433.52		
Target:	Ras		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (144.17 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3067 mL	11.5335 mL	23.0670 mL
		5 mM	0.4613 mL	2.3067 mL	4.6134 mL
		10 mM	0.2307 mL	1.1533 mL	2.3067 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<p>1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (14.42 mM); Clear solution</p> <p>2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 6.25 mg/mL (14.42 mM); Clear solution</p>				

BIOLOGICAL ACTIVITY

Description	PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain ($K_d=4.7 \mu\text{M}$). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity ^[1] .
IC₅₀ & Target	Cnk1 PH-domain ^[1]
In Vivo	PHT-7.3 (200 mg/kg; i.p.; daily; for 20 days) exhibits cytostatic antitumor activity in the mut-KRas(G12S) A549 xenograft and mut-KRasG12V H441 xenograft ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NOD-SCID mice (mut-KRas A549 NSCLC xenografts, mut-KRas H441 NSCLC xenografts) ^[1]
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection, daily, for 20 days
Result:	Exhibited cytostatic antitumor activity in the mut-KRas(G12S) A549 xenograft and mut-KRasG12V H441 xenograft .

CUSTOMER VALIDATION

- Life Sci Alliance. 2021 Jun 29;4(9):e202101095.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Indarte M, et al. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors. Cancer Res. 2019 Jun 15;79(12):3100-3111.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA